Clinical trial · Observational
Fracture Risk Evaluation of Bone Metastases Derived From Carcinoma
Generation of Synthetic Patient Data (RAW) for Risk Evaluation of Bone Metastases Derived From Carcinoma
NCT06524843CI-TRIAL-00098975recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
From the archives of the Rizzoli institute all patients (approximately 750) treated for bone metastases from 01/01/2010 to 31/12/2022. A review will be made from the medical records, radiological imaging, and histological data of these patients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Metastases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients
- description
- Male and female patients affected by bone metastases derived from carcinoma, treated at Rizzoli Orthopaedic Institute from 01/01/2010 to 31/12/2022
- interventionNames
- Other: Analysis
Primary outcomes (1)
- measure
- Creation a dataset of clinical data and diagnostic images
- timeFrame
- At baseline (Day 0)
- description
- Creation a dataset of clinical data and diagnostic images, called RAW, relating to patients suffering from metastatic bone cancer that will be used by the unit UNICH to create innovative models for fracture risk prediction and of life expectancy based on various patient clinical parameters.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of bone metastasis from carcinoma, regardless of the type of carcinoma, and of the number and location of the metastases * Availability of imaging and clinical data * Availability of at least one follow-up during the last 12 months form diagnosis Exclusion Criteria: * At least one inclusion creteria not met
References
Publications (2)
- BACKGROUNDMirels H. Metastatic disease in long bones: A proposed scoring system for diagnosing impending pathologic fractures. 1989. Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S4-13. doi: 10.1097/01.blo.0000093045.56370.dd. PMID 14600587
- BACKGROUNDColeman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s. doi: 10.1158/1078-0432.CCR-06-0931. PMID 17062708